We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Counterfeit Contraceptives Rife in South America

By HospiMedica International staff writers
Posted on 29 Apr 2014
A survey of emergency contraceptive pills (ECPs) in Peru has found that 28% of the batches studied were either of substandard quality or falsified. More...


Researchers at the Georgia Institute of Technology (GATech; Atlanta, USA), The University of Oxford (United Kingdom), and other institutions developed an analytical strategy to assess ECP medicine quality in Peru. For the study, samples of ECPs were purchased at 15 pharmacies and distributors in Lima (Peru). The tablets were collected from 25 different production batches (60 tablets each), encompassing 20 brands labeled as manufactured in nine countries (Argentina, Chile, China, Colombia, Hungary, India, Pakistan, Peru, and Uruguay).

The researchers used a tiered multiplatform approach to examine the tablets. First, ambient mass spectrometry was used to obtain a real-time signature of the tablet's chemical composition. They then examined the presence, identity, and amount of the active ingredient, and tested if the tablet dissolves properly. Since sophisticated fakes might pass all these tests, the researchers also examined excipients, such as lactose and cellulose. In all, 7 different batches showed inadequate release or improper amounts of the active ingredient, levonorgestrel, and one batch was found to contain a wrong active ingredient. The study was published on April 18, 2014, in PLoS One.

“A woman who does not want to get pregnant and takes these emergency contraceptives will get pregnant,” said study author Prof. Facundo Fernández, PhD, of the GATech school of chemistry and biochemistry. “We detected that the active ingredient was not there in one batch, instead those samples had a drug called sulfamethoxazole. It's a very common antibiotic. It can cause serious adverse reactions in some patients.”

Falsified drugs are a major problem in developing countries, and have been reported in Nigeria, Ghana, Kenya, Angola, South America, and even the United States. Just as concerning are other poor quality medications, such as degraded or substandard drugs. Degraded drugs are those that lost their efficacy over time, for example after prolonged exposure to the sun in an open air market. Substandard drugs are made by an approved factory, but do not contain the right active ingredient, contain less active ingredient than they should, or might not dissolve properly.

Related Links:

Georgia Institute of Technology
The University of Oxford



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new 3D heart mapping system visualizes all four chambers in real time (Photo courtesy of UPV)

Whole-Heart Mapping Technology Provides Comprehensive Real-Time View of Arrhythmias

Cardiac arrhythmias can be difficult to diagnose and treat because current mapping systems analyze the heart one chamber at a time. This fragmented view forces clinicians to infer electrical activity they... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.